Oral Corticosteroids' Role in Pediatric Obstructive Sleep Apnea
Key facts
- Who runs it
- Hotel Dieu de France Hospital
- Where
- Lebanon1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 87 people enrolled
- Started
- 9 Dec 2022
- Ended
- 15 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Adenotonsillectomy
- Prednisolone
- Record updated
- 17 April 2025
Who can take part
- Age
- 18 months to 8 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- All children aged between 18 months and 8 years diagnosed with OSAS secondary to adenotonsillar hypertrophy
Who cannot take part
- History of acute or chronic cardiorespiratory neuromuscular, or metabolic diseases
- Chromosomal disorders
- Epilepsy
- Children under 18 months or over 8 years old
- Congenital craniofacial anomalies
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This prospective interventional clinical trial (non-randomized) aims to evaluate oral corticosteroids' role as an alternative to surgery (gold-standard) in the treatment of obstructive sleep apnea in children. It also evaluates the evolution of symptoms' severity as well as any side effects linked to treatment.
Read full original descriptionShow less
This prospective study included children aged between 18 months and 8 years who consulted the same pediatric ENT physician's clinic for OSA secondary to adenotonsillar hypertrophy with no other comorbidities. They were divided into 2 Groups. Children undergoing intracapsular adenotonsillectomy by Coblation™ (Group 1) were compared to those receiving oral prednisolone at a dose of 1mg/kg for 5 days and 1 month of intranasal corticosteroids (Group 2). The follow-up tools were the Pediatric Sleep Questionnaire (PSQ) score and the size of the tonsils (Brodsky classification) evaluated at 1, 3 and 6 months.
The 2 groups in the trial
- Patients undergoing surgical treatment (adenotonsillectomy).Existing treatment, for comparison
Children undergoing adenoidectomy and intracapsular tonsillectomy using Coblation™, by the same surgeon at HDF.
Treatment: Adenotonsillectomy
- Patients undergoing medical treatment (short-term and low dose oral corticosteroids).Treatment being tested
The second Group includes children whose parents have refused surgery despite informed understanding of the therapeutic algorithm of OSA. They received medical treatment consisting of a 1-month treatment with intranasal corticosteroids, coupled with a 5-day course of oral corticosteroids (prednisolone) at a safe dose of 1mg/kg.
Treatment: Prednisolone
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Oral Corticosteroids' Role in Pediatric Obstructive Sleep Apnea, a Non-Randomized Controlled Trial.
- Record updated
- 17 April 2025